VYNE Therapeutics Announces Phase Ib Data for FMX114 from Phase Ib/IIa Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics, Inc. announced that it has completed the Phase Ib portion of a Phase Ib/IIa clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis